217 related articles for article (PubMed ID: 23247012)
1. Effects of solifenacin in patients with neurogenic detrusor overactivity as a result of spinal cord lesion.
Krebs J; Pannek J
Spinal Cord; 2013 Apr; 51(4):306-9. PubMed ID: 23247012
[TBL] [Abstract][Full Text] [Related]
2. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity.
Ronchi P; Gravina GL; Galatioto GP; Costa AM; Martella O; Vicentini C
Neurourol Urodyn; 2009; 28(1):52-7. PubMed ID: 18671288
[TBL] [Abstract][Full Text] [Related]
3. Co-administration of an α(1) -blocker improves the efficacy and safety of antimuscarinic agents in rats with detrusor overactivity.
Nagase K; Ito H; Aoki Y; Tanase K; Akino H; Yokoyama O
Int J Urol; 2011 Dec; 18(12):836-43. PubMed ID: 21995543
[TBL] [Abstract][Full Text] [Related]
4. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury.
Wöllner J; Pannek J
Spinal Cord; 2016 Jan; 54(1):78-82. PubMed ID: 26503222
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of solifenacin to treat overactive bladder symptoms in patients with idiopathic normal pressure hydrocephalus: an open-label, multicenter, prospective study.
Chung JH; Lee JY; Kang DH; Ha US; Lee SH; Ham WS; Cho KS; Han JH; Park J; Yoo TK; Lee SW
Neurourol Urodyn; 2012 Sep; 31(7):1175-80. PubMed ID: 22674356
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
[TBL] [Abstract][Full Text] [Related]
7. Solifenacin succinate for the treatment of symptoms of overactive bladder.
Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
[TBL] [Abstract][Full Text] [Related]
8. Prospective open label study of solifenacin for overactive bladder in children.
Bolduc S; Moore K; Nadeau G; Lebel S; Lamontagne P; Hamel M
J Urol; 2010 Oct; 184(4 Suppl):1668-73. PubMed ID: 20728124
[TBL] [Abstract][Full Text] [Related]
9. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study.
Amarenco G; Sutory M; Zachoval R; Agarwal M; Del Popolo G; Tretter R; Compion G; De Ridder D
Neurourol Urodyn; 2017 Feb; 36(2):414-421. PubMed ID: 26714009
[TBL] [Abstract][Full Text] [Related]
10. Supratrigonal cystectomy with Hautmann pouch as treatment for neurogenic bladder in spinal cord injury patients: long-term functional results.
Gobeaux N; Yates DR; Denys P; Even-Schneider A; Richard F; Chartier-Kastler E
Neurourol Urodyn; 2012 Jun; 31(5):672-6. PubMed ID: 22532256
[TBL] [Abstract][Full Text] [Related]
11. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.
Hsiao SM; Chang TC; Wu WY; Chen CH; Yu HJ; Lin HH
J Obstet Gynaecol Res; 2011 Aug; 37(8):1084-91. PubMed ID: 21501328
[TBL] [Abstract][Full Text] [Related]
12. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
[TBL] [Abstract][Full Text] [Related]
13. Overactive bladder syndrome: what is the role of evidence of detrusor overactivity in the cystometric study?
Vecchioli-Scaldazza C; Grinta R
Minerva Urol Nefrol; 2010 Dec; 62(4):355-61. PubMed ID: 20944536
[TBL] [Abstract][Full Text] [Related]
14. Are oxybutynin and trospium efficacious in the treatment of detrusor overactivity in spinal cord injury patients?
Hadiji N; Previnaire JG; Benbouzid R; Robain G; Leblond C; Mieusset R; Enjalbert M; Soler JM
Spinal Cord; 2014 Sep; 52(9):701-5. PubMed ID: 25047051
[TBL] [Abstract][Full Text] [Related]
15. Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder.
Tanaka Y; Masumori N; Tsukamoto T
Int J Urol; 2010 Sep; 17(9):796-800. PubMed ID: 20649825
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia.
Chen CY; Liao CH; Kuo HC
Spinal Cord; 2011 May; 49(5):659-64. PubMed ID: 21243000
[TBL] [Abstract][Full Text] [Related]
17. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
Chen YC; Kuo HC
Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
[TBL] [Abstract][Full Text] [Related]
18. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
